Wilson W. Cheung designated Tessa Therapeutics Chief Financial Officer

KUALA LUMPUR, April 5 (Bernama) -- Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumours, has announced the appointment of Wilson W. Cheung as its chief financial officer, effective April 1, 2022.

He brings to Tessa more than 25 years of experience in accounting and corporate finance, compliance, and corporate leadership at both public and private companies with presence in both the U.S. and China.

Cheung joins Tessa as the Company is advancing the clinical exploration of its autologous CD30-CAR-T therapy (TT11) and its allogeneic CD30.CAR EBVST therapy (TT11X) programs.

As CFO, he will lead Tessa’s overall fiscal management, as well as the company’s investor relations, and business development strategy, initially operating in the U.S. before relocating to Tessa’s global headquarters in Singapore, and report to John Ng, CTO and acting CEO.

“Adding a Chief Financial Officer with Wilson’s track record of success, including private placement, IPO and public company experience, marks another important inflection for Tessa following the recent presentation of compelling clinical data from our TT11 and TT11X cell therapy programs at the 63rd Annual Meeting of the American Society of Hematology (ASH),” stated Ng in a statement.

“As CFO, Wilson will be our emissary to the investment community, while ensuring Tessa has the proper financial structures and discipline in place to enable our near-term and longer-range growth objectives.”

Cheung who served as EVP and CFO at Apollomics Inc prior to Tessa, is a Certified Public Accountant (CPA), having begun his career in public accounting with KPMG LLP and Deloitte LLP. He holds a B.A. in Economic-Business from the University of California, Los Angeles (UCLA), and is a Certified Director of Corporate Governance from UCLA’s Executive Program.

“I am excited to join the team at Tessa Therapeutics, especially at such an exciting time for the Company. With multiple milestones on the horizon, I look forward to working with John, the Board of Directors and my new colleagues to build Tessa into a global CAR-T leader,” said Cheung.

For more information on Tessa, visit www.tessacell.com.

-- BERNAMA